Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/hdi.12951 http://scihub22266oqcxt.onion/10.1111/hdi.12951 34133062!8444855!34133062     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hemodial+Int 2021 ; 25 (4): 515-522 Nephropedia Template TP {{tp|p=34133062|t=2021. Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis |pdf=|usr=}}{{34133062}} gab.com Text Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis JO: Hemodial Int http://www.kidney.de/pget.php?&tw=1&pmid=34133062 #FOAvip BACKGROUND: The passive immunization of patients with SARS-CoV2 with convalescent plasma (CP) is theoretically beneficial in patients with end-stage renal disease who are immunosuppressed and unable to mount an adequate immune response. Hence, this study was conducted to evaluate the safety and efficacy of CP in patients with chronic kidney disease on hemodialysis with moderate-to-severe SARS-CoV2 infection. METHODS: A prospective observational cohort study was conducted in consecutive 68 moderate-to-severe SARS-CoV2 infected patients who were on maintenance hemodialysis or with acute worsening of chronic kidney disease which required initiation of hemodialysis. Patients who received CP were compared with those who did not. The primary outcome was death during hospitalization. Clinical characteristics, duration of hospitalization and inflammatory parameters were compared between the two groups. A subgroup analysis was done to find whether early initiation of plasma was associated with better outcome. RESULTS: Sixteen patients (44%) in the plasma group and 14 (45%) patients in the control group died during hospitalization (p = 0.95). The median duration of hospitalization was 9 (6-14) days in the plasma group and 9 (6-16) in the control group (p = 0.60). There was no difference in mortality or duration of hospitalization with respect to early initiation of CP (p = 0.29). Fistula thrombosis occurred in two patients (11.1%) in the plasma group. CONCLUSION: Therapy with CP does not appear to confer any clinical benefit in moderate-to-severe SARS-CoV-2 infected patients with chronic kidney disease on hemodialysis. Twit Text FOAVip Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis ????Hemodial Int http://www.kidney.de/pget.php?&tw=1&pmid=34133062 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34133062 #FOAvip English Wikipedia <ref>{{Cite pmid|34133062}}</ref> Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis #MMPMID34133062 Sajmi S; Goutham K; Arumugam V; Gopalakrishnan N; Lamech TM; Aiswarya D; Krishna R; Vathsalyan P; Kannan BS; Solomon D; Nithya G; Sastry BVRH; Sakthirajan R Hemodial Int 2021[Oct]; 25 (4): 515-522 PMID34133062show ga BACKGROUND: The passive immunization of patients with SARS-CoV2 with convalescent plasma (CP) is theoretically beneficial in patients with end-stage renal disease who are immunosuppressed and unable to mount an adequate immune response. Hence, this study was conducted to evaluate the safety and efficacy of CP in patients with chronic kidney disease on hemodialysis with moderate-to-severe SARS-CoV2 infection. METHODS: A prospective observational cohort study was conducted in consecutive 68 moderate-to-severe SARS-CoV2 infected patients who were on maintenance hemodialysis or with acute worsening of chronic kidney disease which required initiation of hemodialysis. Patients who received CP were compared with those who did not. The primary outcome was death during hospitalization. Clinical characteristics, duration of hospitalization and inflammatory parameters were compared between the two groups. A subgroup analysis was done to find whether early initiation of plasma was associated with better outcome. RESULTS: Sixteen patients (44%) in the plasma group and 14 (45%) patients in the control group died during hospitalization (p = 0.95). The median duration of hospitalization was 9 (6-14) days in the plasma group and 9 (6-16) in the control group (p = 0.60). There was no difference in mortality or duration of hospitalization with respect to early initiation of CP (p = 0.29). Fistula thrombosis occurred in two patients (11.1%) in the plasma group. CONCLUSION: Therapy with CP does not appear to confer any clinical benefit in moderate-to-severe SARS-CoV-2 infected patients with chronic kidney disease on hemodialysis. |*COVID-19/therapy[MESH] |*RNA, Viral[MESH] |COVID-19 Serotherapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Prospective Studies[MESH] |Renal Dialysis/adverse effects[MESH] |SARS-CoV-2[MESH]Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patien(epmc).pdf DeepDyve Pubget Overpricing